This application proposes to continue the Rocky Mountain Regional Center of Excellence (RMRCE) for Biodefense and Emerging Infectious Diseases Research located in Region VIII. The RMRCE consists of a highly integrated consortium of universities and federal agencies with significant interactions with multiple commercial entities. The RMRCE has completed three years since funding, and for the renewal, plans to build upon the strengths, synergies, and newly developed expertise that have emerged from the past efforts of this program. The renewed research program will be centered around three integrated research focus (IRF) groups that target the thematic research efforts on 1) immunomodulation, adjuvants and vaccines;2) bacterial therapeutics;and 3) viral therapeutics. The research and product development efforts of the IRF groups will be facilitated by five scientific cores. Research efforts will be directed at a variety of NIH Category A-C pathogens and will exploit the extensive BSL3 facilities within the region so that studies will be performed almost entirely with virulent forms of the pathogens. Training objectives of the RMRCE will include a competitive career development program structured similar to the NIH K-awards and group training efforts for biosafety and product development. The progress of individual projects and cores, as well as the progress and synergy of the overall program will be continually monitored and managed via a robust evaluation process that encompasses input from NIH program personnel, RMRCE leadership from multiple institutions, and external reviewers. Adding to the flexibility of this program will be the continuation of a highly successful program for the funding of Developmental Research Projects. Overall the goals of the RMRCE are summarized as: 1) continue investigator-directed research programs that address basic and translational research for biodefense and emerging infectious diseases, including understudied Select Agents;2) provide career development and group training that exploits the strengths of the RMRCE;3) utilize well integrated scientific core facilities to accelerate research and product development activities;4) enable programmatic flexibility and responsiveness through a strong project evaluation process and continuation of a program for Developmental Research Projects;and 5) establish an emergency response program that is based on the resources of the RMRCE and that is managed by a single individual.

Public Health Relevance

The RMRCE activities are directed towards fulfilling the RCE program mandate of establishing and maintaining a strong infrastructure, multifaceted basic and applied research programs, as well as translational and educational activities that will facilitate development of the next generation of therapeutics and vaccines against Category A-C and other emerging infectious disease pathogens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-07
Application #
8070336
Study Section
Special Emphasis Panel (ZAI1-DDS-M (J2))
Program Officer
Peters, Kent
Project Start
2005-06-01
Project End
2014-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
7
Fiscal Year
2011
Total Cost
$7,054,719
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Microbiology/Immun/Virology
Type
Schools of Veterinary Medicine
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Webb, Jessica R; Price, Erin P; Somprasong, Nawarat et al. (2018) Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Future Microbiol 13:1403-1418
York, Joanne; Nunberg, Jack H (2018) A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity. Methods Mol Biol 1604:157-167
Rhodes, Katherine A; Somprasong, Nawarat; Podnecky, Nicole L et al. (2018) Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology 164:1156-1167
Cummings, Jason E; Slayden, Richard A (2017) Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. PLoS Negl Trop Dis 11:e0005209
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Randall, Linnell B; Georgi, Enrico; Genzel, Gelimer H et al. (2017) Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother 72:1258-1260
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:

Showing the most recent 10 out of 258 publications